Comparison of the antihypertensive effect of imidapril and enalapril in the treatment of mild to moderate essential hypertension: A randomized, double-blind, parallel-group study

Current Therapeutic Research - Clinical and Experimental

Volumn 62, Issue 6, 2001, Pages 437-450

  Van Der Does, Reinhard ^a   Euler, Rolf ^b  

^a IST GmbH   (Germany)

^b MERCK KGAA   (Germany)

Author keywords

Antihypertensive; Enalapril; Essential hypertension; Imidapril

Indexed keywords

ENALAPRIL; IMIDAPRIL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; ESSENTIAL HYPERTENSION; FEMALE; GASTRITIS; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; UPPER RESPIRATORY TRACT INFECTION;

EID: 0034979674     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(01)80055-2     Document Type: Article

References (15)

1. Converting enzyme inhibitors in cardiovascular therapy: Current status and future potential
2. Pharmacological studies on (4S)-1-methyl-3-[(2S)-2-{N-((1S)-1-ethoxycarbonyl-3- phenylpropyl)amino}propionyl]-2-oxo-imidazoline-4-carboxylic acid hydrochloride (TA-6366), a new ACE inhibitor: I. ACE inhibitory and antihypertensive activities
3. Dose finding studies with imidapril - A new ACE inhibitor
4. An 8 week placebo-controlled dose titration study of imidapril in the treatment of mild to moderate essential hypertension
5. Dose-finding study of imidapril, a novel angiotensin converting enzyme inhibitor, in patients with stable chronic heart failure
6. Effect of ACE/TA-6366 (imidapril hydrochloride), angiotensin-converting enzyme inhibitor, on diurnal blood pressure change in essential hypertension
7. Efficacy and safety of imidapril (ACE/TA-6366), angiotensin I converting enzyme inhibitor, in monotherapy on essential hypertension - Multiclinic open trial
8. Efficacy and safety of imidapril hydrochloride (ACE/TA-6366), angiotensin converting enzyme inhibitor, on essential hypertension in the long-term treatment
9. Circadian variation in blood pressure and pharmacokinetics following single and consecutive doses of angiotensin-converting enzyme inhibitor ACE/TA-6366 (imidapril hydrochloride) in patients with essential hypertension
10. Imidapril hydrochloride in essential hypertension: A double-blind comparative study using enalapril maleate as a control
11. An updated review of its therapeutic use in essential hypertension and heart failure
12. A reappraisal of its pharmacology and therapeutic use in hypertension
13. Adverse effects of angiotensin-converting enzyme (ACE) inhibitors. An update
14. Difference in the incidence of cough induced by angiotensin converting enzyme inhibitors: A comparative study using imidapril hydrochloride and enalapril maleate